20/20 OptimEyes

Apply Today

20/20 OptimEyes

20/20 OptimEyes is a McMaster spinout creating highly effective drug delivery systems to treat ocular conditions. We are currently commercializing an improved eye drop that allows for less frequent dosing, which is more convenient for patients, but more importantly reduces side effects of current treatments. This technology is patent pending, with a unique triblock copolymer providing its favourable properties. Our lead indication is dry eye disease, with glaucoma and ocular infections also being explored.

Some Other Companies see all